Cholecalciferol

Evidence Level: L5

Predicted Indications: 4

Cholecalciferol

Pharmacist Assessment Report

One-Sentence Summary

The TxGNN model (deep learning) predicts that cholecalciferol (vitamin D3) may be effective for acromesomelic dysplasia, Campailla Martinelli type, a rare genetic skeletal dysplasia. This score comes from the TxGNN model and may reflect similarities the model learned between related diseases, not biological evidence. There are 0 clinical trials and 0 publications supporting this prediction, so it rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Osteoporosis, vitamin D deficiency, osteomalacia, rickets and related conditions (relations recorded in the knowledge graph; no approved indication text is available in the data compiled for this report)
Predicted New Indication	Acromesomelic dysplasia, Campailla Martinelli type
TxGNN Prediction Score	0.9978
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Cholecalciferol is a vitamin D3 precursor that is converted in the body to active vitamin D, which supports calcium and phosphate handling and bone mineralisation. The TxGNN model (deep learning) score may reflect similarities the model learned between related diseases, not biological evidence.

Acromesomelic dysplasia is a rare inherited skeletal disorder. It is generally thought to involve bone growth signalling pathways rather than vitamin D or mineral deficiency. The data compiled for this report establish no plausible direct mechanistic link between cholecalciferol and this condition. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence of a therapeutic effect.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 13835E	Fosamax Plus 70 mg/140 mcg	Oral tablet, 70 mg (as alendronate sodium) with 140 micrograms colecalciferol	Not provided in the data compiled for this report

This is the only ARTG entry found, and it is a combination product (alendronate plus colecalciferol). It therefore does not show how cholecalciferol on its own is approved or marketed in Australia.

Safety Considerations

Knowledge-graph contraindication relations (not label text): hypertension, kidney disease, liver disease, gallbladder disease, gastritis, sarcoidosis, diabetes mellitus, diabetic ketoacidosis, atrial fibrillation, hyperparathyroidism, osteitis fibrosa, hypercalcaemia, nephrocalcinosis, phosphorus metabolism disease, blood coagulation disease, sickle cell anaemia, primary hyperoxaluria, hereditary haemochromatosis, Wilson disease, hyperlipidaemia, breast carcinoma and prostate cancer, among others.
Drug interactions: 56 interactions were identified. Of the 20 listed in the data compiled for this report, the following are rated Major: calcifediol, calcitriol, dihydrotachysterol and doxercalciferol. These are other vitamin D agents, so combining them risks additive vitamin D effects. Many others are rated Moderate, including thiazide diuretics, barbiturates, carbamazepine, digoxin and digitoxin, and bile acid sequestrants (cholestyramine, colestipol, colesevelam).

Please refer to the TGA-approved Product Information (PI) for label warnings and contraindications, which were not available for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by a TxGNN model (deep learning) score. No clinical trials or publications address this disease, and no plausible mechanism has been established. The evidence level is therefore L5.

To proceed, the following is needed:

Mechanistic evidence linking vitamin D biology to the pathway underlying this skeletal dysplasia
Any preclinical, case-based or clinical data in this specific condition
Detailed mechanism of action data and TGA PI warnings and contraindications for cholecalciferol
Confirmation of how cholecalciferol is licensed as a single ingredient in Australia, as the only entry found is a combination product

For context, other TxGNN predictions for this drug, such as renal osteodystrophy, have more supporting evidence and may be better candidates for further review.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Cholecalciferol

Table of Contents

Pharmacist Assessment Report